Novartis to save at least $1 billion by 2024 thanks to simplified structure

[April 04, 2022]  ZURICH (Reuters) -Novartis said on Monday it was integrating its pharmaceuticals and oncology units into an innovative medicines (IM) business to simplify its structure, targeting savings of at least $1 billion by 2024.

"Integrating pharmaceuticals and oncology business units into an innovative medicines (IM) business with separate U.S. and international commercial organizations will increase focus, strengthen competitiveness and drive synergies," the Swiss pharmaceutical company said in a statement.

It said it expects selling, general and administrative savings of at least $1 billion to be fully embedded by 2024 as a result of these changes.

The company based in Basel appointed Marie-France Tschudin as president of innovative medicines international and chief commercial officer, and Victor Bulto as president of innovative medicines in the United States.
 

The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/

Steffen Lang will take over as president operations, while

Shreeram Aradhye becomes president global drug development and chief medical officer. Susanne Schaffert, Robert Weltevreden and John Tsai are leaving Novartis, the company said.

Value creation through these operational improvements should ensure at least 4% sales growth in constant currency through 2026. Novartis also expects to deliver at the high end of its IM margin guidance of high 30s in the medium term and 40% or more in the mid- to long-term.

(Reporting by Silke Koltrowitz, Editing by Miranda Murray)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.